Net Income

A new $500M fund aims to profit from the U.S. housing shortage by banking on its scarcest resource: land. But can it deliver for investors and builders?

U Power (UCAR) presents its AI-driven energy grid strategy at a key conference, betting on a tech pivot to reignite investor interest after a steep decline.

Mark Hunt, the architect of SIM's rise to an $86B powerhouse, has stepped down, leaving questions about the future of the firm he built from the ground up.

Winning a top EdTech award, K12 Tutoring's success is backed by rigorous studies showing major gains, especially for students who need it most.

A new partnership signals a major shift in the art market, placing scientific conservation at the heart of determining an asset's long-term value.

Anheuser-Busch places a high-stakes bet on NÜTRL for the 2026 World Cup, aiming to dominate the competitive hard seltzer market with a global play.

LP's 7% dividend hike reflects strong financials and a cautiously optimistic outlook for the evolving construction and housing markets in 2026.

With triple-digit loan volume growth and a landmark AAA rating, Figure Technology Solutions' latest results suggest tokenized assets are finally breaking through.

Elanco's founding chairman and innovation head are leaving, marking a pivotal leadership shift as the animal health giant charts its post-spin-off future.

Toronto's Xanadu unveils a breakthrough quantum algorithm for chemistry while preparing for a major public listing via a $500 million SPAC deal.

The exclusive access app is expanding beyond dining, using AI and human editors to solve 'cultural overwhelm' for its affluent, globe-trotting members.

A new ETF, EXEQ, uses AI to score and invest in corporate leadership, aiming to turn a qualitative trait into a data-driven source of returns.

With a $15 million funding boost, Nasus Pharma is accelerating its powder-based intranasal epinephrine, NS002, challenging the EpiPen's dominance.

A new online pharmacy is challenging the 'prescribe and forget' model for weight loss drugs, offering integrated clinical care to combat safety concerns.

The firm reports a $195M cash reserve but a wider net loss as it nears crucial data readouts for its novel depression and anxiety drug candidates.

With 15 'Best Bank' awards fueled by client feedback and record SBA lending, Huntington Bank demonstrates a winning formula for business banking success.

Iterum Therapeutics secures key Medicare access for its antibiotic ORLYNVAH™, but a costly FDA trial requirement for a new use casts a shadow on its future.

Alto Neuroscience completes enrollment for a trial of its skin patch drug, ALTO-101, offering new hope for the millions battling cognitive decline in schizophrenia.

The Canadian restaurant giant defied a tough market in 2025, posting record sales and boosting investor payouts through strategic promotions and delivery.

Chinese data center giant VNET promotes Peter Zhang to SVP, signaling a focus on stability and governance as it navigates rapid AI-driven growth.